- Home
- TLPH vs DWTX Comparison
TLPH vs DWTX Comparison
Compare TLPH & DWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLPH
- DWTX
- Stock Information
- Founded
- TLPH 2005
- DWTX 2012
- Country
- TLPH United States
- DWTX United States
- Employees
- TLPH N/A
- DWTX N/A
- Industry
- TLPH Biotechnology: Pharmaceutical Preparations
- DWTX
- Sector
- TLPH Health Care
- DWTX
- Exchange
- TLPH Nasdaq
- DWTX NYSE
- Market Cap
- TLPH 10.6M
- DWTX 9.2M
- IPO Year
- TLPH 2011
- DWTX N/A
- Fundamental
- Price
- TLPH $0.44
- DWTX $4.76
- Analyst Decision
- TLPH Strong Buy
- DWTX Strong Buy
- Analyst Count
- TLPH 1
- DWTX 1
- Target Price
- TLPH $6.00
- DWTX $10.00
- AVG Volume (30 Days)
- TLPH 31.7K
- DWTX 54.3K
- Earning Date
- TLPH 08-13-2025
- DWTX 08-14-2025
- Dividend Yield
- TLPH N/A
- DWTX N/A
- EPS Growth
- TLPH N/A
- DWTX N/A
- EPS
- TLPH N/A
- DWTX N/A
- Revenue
- TLPH $27,000.00
- DWTX N/A
- Revenue This Year
- TLPH N/A
- DWTX N/A
- Revenue Next Year
- TLPH $14,533.26
- DWTX N/A
- P/E Ratio
- TLPH N/A
- DWTX N/A
- Revenue Growth
- TLPH N/A
- DWTX N/A
- 52 Week Low
- TLPH $0.44
- DWTX $1.62
- 52 Week High
- TLPH $1.19
- DWTX $29.28
- Technical
- Relative Strength Index (RSI)
- TLPH 31.91
- DWTX N/A
- Support Level
- TLPH $0.45
- DWTX N/A
- Resistance Level
- TLPH $0.52
- DWTX N/A
- Average True Range (ATR)
- TLPH 0.03
- DWTX 0.00
- MACD
- TLPH -0.00
- DWTX 0.00
- Stochastic Oscillator
- TLPH 0.00
- DWTX 0.00
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About DWTX DOGWOOD THERAPEUTICS INC
Dogwood Therapeutics Inc, formerly Virios Therapeutics Inc, is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response, such as fibromyalgia (FM) and long COVID (LC). Its product candidates include IMC-1 and IMC-2. IMC-1 is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.